Showing 1 - 9 results of 9 for search 'Massimo Di Nicola', query time: 0.03s Refine Results
  1. 1
    Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer

    Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer by Francesco Mainini, Francesca De Santis, Giovanni Fucà, Massimo Di Nicola, Licia Rivoltini, Michael Eccles

    Published 2021-07-01
    Get full text
    Article
  2. 2
    A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy

    A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy by Alessandro Satta, Giulia Grazia, Francesco Caroli, Barbara Frigerio, Massimo Di Nicola, Francesco Raspagliesi, Delia Mezzanzanica, Nadia Zaffaroni, Alessandro Massimo Gianni, Andrea Anichini, Mariangela Figini

    Published 2019-10-01
    Get full text
    Article
  3. 3
    SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities

    SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities by Sabina Sangaletti, Giovanna Talarico, Claudia Chiodoni, Barbara Cappetti, Laura Botti, Paola Portararo, Alessandro Gulino, Francesca Maria Consonni, Antonio Sica, Antonio Sica, Giovanni Randon, Massimo Di Nicola, Claudio Tripodo, Mario P. Colombo

    Published 2019-06-01
    Get full text
    Article
  4. 4
    ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

    ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy by Hendrik-Tobias Arkenau, Jean-Yves Douillard, Nicolas Penel, Teresa Amaral, Ahmad Awada, Emiliano Calvo, Viktor Gruenwald, Jose Luis Perez-Gracia, Ruth Vera, Martijn P Lolkema, Gyorgy Bodoky, Massimo Di Nicola, Miguel F Sanmamed

    Published 2020-05-01
    Get full text
    Article
  5. 5
    Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade

    Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade by Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà, Biagio Paolini, Barbara Vergani, Valeria Beretta, Silvia Damian, Matteo Duca, Sara Cresta, Michele Magni, Biagio Eugenio Leone, Chiara Castelli, Filippo de Braud, Francesca De Santis, Massimo Di Nicola

    Published 2024-02-01
    Get full text
    Article
  6. 6
    A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis

    A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis by Mara Lecchi, Paolo Verderio, Vera Cappelletti, Francesca De Santis, Biagio Paolini, Melissa Monica, Sabina Sangaletti, Serenella Maria Pupa, Marilena Valeria Iorio, Giulia Bianchi, Massimiliano Gennaro, Giovanni Fucà, Filippo De Braud, Elda Tagliabue, Massimo Di Nicola

    Published 2021-05-01
    Get full text
    Article
  7. 7
    Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies

    Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclon... by Maria Silvia Cona, Mara Lecchi, Sara Cresta, Silvia Damian, Michele Del Vecchio, Andrea Necchi, Marta Maria Poggi, Daniele Raggi, Giovanni Randon, Raffaele Ratta, Diego Signorelli, Claudio Vernieri, Filippo de Braud, Paolo Verderio, Massimo Di Nicola

    Published 2019-02-01
    Get full text
    Article
  8. 8
    520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors

    520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with a... by Rui Wang, Ivan Borbath, Patrícia Martin, Armando Santoro, Bernard Doger, Elena Garralda, Oliver Bechter, Giovanni Abbadessa, Debbie Robbrecht, Grob Jean-Jacques, Butler Marcus, Cheng Tina, Bennouna Jaafar, Massimo Di Nicola, Alejo Rodriguez -Vida, Dirk Schadendof, Brigitte Demers, Amele Amrate, Tun Tun Lin, Manisha Brahmachary, Joon Sange Lee, Joachim Theilhaber, Rob Pomponio

    Published 2021-11-01
    Article
  9. 9
    Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

    Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical stu... by Debbie Robbrecht, Jean‐Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Ivan Borbath, Marcus O. Butler, Tina Cheng, Patricia Martin Romano, Elvire Pons‐Tostivint, Massimo Di Nicola, Giuseppe Curigliano, Min‐Hee Ryu, Alejo Rodriguez‐Vida, Dirk Schadendorf, Elena Garralda, Giovanni Abbadessa, Brigitte Demers, Amele Amrate, Hong Wang, Joon Sang Lee, Robert Pomponio, Rui Wang

    Published 2024-02-01
    Get full text
    Article

Search Tools: